These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 12852342

  • 1. [Chemotherapy-induced diarrhea].
    Kobayashi K.
    Gan To Kagaku Ryoho; 2003 Jun; 30(6):765-71. PubMed ID: 12852342
    [Abstract] [Full Text] [Related]

  • 2. Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea.
    Takasuna K, Hagiwara T, Watanabe K, Onose S, Yoshida S, Kumazawa E, Nagai E, Kamataki T.
    Cancer Chemother Pharmacol; 2006 Oct; 58(4):494-503. PubMed ID: 16437251
    [Abstract] [Full Text] [Related]

  • 3. Control of irinotecan-induced diarrhea by octreotide after loperamide failure.
    Barbounis V, Koumakis G, Vassilomanolakis M, Demiri M, Efremidis AP.
    Support Care Cancer; 2001 Jun; 9(4):258-60. PubMed ID: 11430421
    [Abstract] [Full Text] [Related]

  • 4. Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment.
    Saliba F, Hagipantelli R, Misset JL, Bastian G, Vassal G, Bonnay M, Herait P, Cote C, Mahjoubi M, Mignard D, Cvitkovic E.
    J Clin Oncol; 1998 Aug; 16(8):2745-51. PubMed ID: 9704727
    [Abstract] [Full Text] [Related]

  • 5. Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients.
    Takeda Y, Kobayashi K, Akiyama Y, Soma T, Handa S, Kudoh S, Kudo K.
    Int J Cancer; 2001 Apr 15; 92(2):269-75. PubMed ID: 11291056
    [Abstract] [Full Text] [Related]

  • 6. [Management of chemotherapy induced diarrhea].
    Schultz M, Schölmerich J, Kullmann F.
    Z Gastroenterol; 2004 Jun 15; 42(6):527-38. PubMed ID: 15190449
    [Abstract] [Full Text] [Related]

  • 7. Therapeutic response to octreotide in patients with refractory CPT-11 induced diarrhea.
    Pro B, Lozano R, Ajani JA.
    Invest New Drugs; 2001 Jun 15; 19(4):341-3. PubMed ID: 11561696
    [Abstract] [Full Text] [Related]

  • 8. Prevention of irinotecan-induced diarrhoea by oral carbonaceous adsorbent (Kremezin) in cancer patients.
    Maeda Y, Ohune T, Nakamura M, Yamasaki M, Kiribayashi Y, Murakami T.
    Oncol Rep; 2004 Sep 15; 12(3):581-5. PubMed ID: 15289841
    [Abstract] [Full Text] [Related]

  • 9. Octreotide LAR resolves severe chemotherapy-induced diarrhoea (CID) and allows continuation of full-dose therapy.
    Rosenoff SH.
    Eur J Cancer Care (Engl); 2004 Sep 15; 13(4):380-3. PubMed ID: 15305907
    [Abstract] [Full Text] [Related]

  • 10. [A case-control study of prevention of irinotecan-induced diarrhea: the reducing side effects of irinotecan by oral alkalization combined with control of defecation].
    Takeda Y, Kobayashi K, Akiyama Y, Soma T, Handa S, Kudoh S, Kudo K.
    Gan To Kagaku Ryoho; 2002 Jul 15; 29(7):1171-7. PubMed ID: 12145998
    [Abstract] [Full Text] [Related]

  • 11. Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer.
    Mori K, Kondo T, Kamiyama Y, Kano Y, Tominaga K.
    Cancer Chemother Pharmacol; 2003 May 15; 51(5):403-6. PubMed ID: 12687289
    [Abstract] [Full Text] [Related]

  • 12. [Taxotere (docetaxel) and CPT 11 (irinotecan): phase I trials].
    Couteau C, Yakendji K, Terret C, Goncalves E, Armand JP.
    Bull Cancer; 1996 Jan 15; 83(1):3-10. PubMed ID: 8672854
    [Abstract] [Full Text] [Related]

  • 13. New approaches to prevent intestinal toxicity of irinotecan-based regimens.
    Alimonti A, Gelibter A, Pavese I, Satta F, Cognetti F, Ferretti G, Rasio D, Vecchione A, Di Palma M.
    Cancer Treat Rev; 2004 Oct 15; 30(6):555-62. PubMed ID: 15325035
    [Abstract] [Full Text] [Related]

  • 14. Phase I/IIA randomized study of PHY906, a novel herbal agent, as a modulator of chemotherapy in patients with advanced colorectal cancer.
    Farrell MP, Kummar S.
    Clin Colorectal Cancer; 2003 Feb 15; 2(4):253-6. PubMed ID: 12620148
    [No Abstract] [Full Text] [Related]

  • 15. Prevention of irinotecan-induced diarrhea by oral sodium bicarbonate and influence on pharmacokinetics.
    Tamura T, Yasutake K, Nishisaki H, Nakashima T, Horita K, Hirohata S, Ishii A, Hamano K, Aoyama N, Shirasaka D, Kamigaki T, Kasuga M.
    Oncology; 2004 Feb 15; 67(5-6):327-37. PubMed ID: 15713987
    [Abstract] [Full Text] [Related]

  • 16. Weekly administration of irinotecan (CPT-11) plus cisplatin for refractory or relapsed small cell lung cancer.
    Ando M, Kobayashi K, Yoshimura A, Kurimoto F, Seike M, Nara M, Moriyama G, Mizutani H, Hibino S, Gemma A, Okano T, Shibuya M, Kudoh S.
    Lung Cancer; 2004 Apr 15; 44(1):121-7. PubMed ID: 15013590
    [Abstract] [Full Text] [Related]

  • 17. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea.
    Abigerges D, Armand JP, Chabot GG, Da Costa L, Fadel E, Cote C, Hérait P, Gandia D.
    J Natl Cancer Inst; 1994 Mar 16; 86(6):446-9. PubMed ID: 8120919
    [Abstract] [Full Text] [Related]

  • 18. Novel agents that potentially inhibit irinotecan-induced diarrhea.
    Yang X, Hu Z, Chan SY, Chan E, Goh BC, Duan W, Zhou S.
    Curr Med Chem; 2005 Mar 16; 12(11):1343-58. PubMed ID: 15975002
    [Abstract] [Full Text] [Related]

  • 19. [Preventive effect of TJ-14, a kampo (Chinese herb) medicine, on diarrhea induced by irinotecan hydrochloride (CPT-11)].
    Sakata Y, Suzuki H, Kamataki T.
    Gan To Kagaku Ryoho; 1994 Jul 16; 21(8):1241-4. PubMed ID: 8031168
    [Abstract] [Full Text] [Related]

  • 20. Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure of loperamide treatment.
    Lenfers BH, Loeffler TM, Droege CM, Hausamen TU.
    Ann Oncol; 1999 Oct 16; 10(10):1251-3. PubMed ID: 10586346
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.